| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is Polo-like kinase 1 (Plk1), a serine/threonine kinase that regulates mitotic entry, spindle assembly, and cytokinesis. SBE13 is a type II inhibitor that binds to the inactive conformation of Plk1, exploiting a second hydrophobic pocket that is only accessible when the kinase domain is in its inactive state. This mechanism provides exceptional selectivity over Plk2 and Plk3, which are highly homologous in their ATP-binding pockets.
|
|---|---|
| ln Vitro |
SBE13, with an EC50 of 18 μM, causes apoptosis and dramatically inhibits cell growth in HeLa cells [1]. NIH-3T3 cells' caspase 3/7 activity is unaffected by SBE13 (1-100 μM). Following treatment of primary cells, SBE13 (66 and 100 μM) does not alter morphology. G0/G1 arrest is indicated by a reduction in pRb staining in primary cells caused by SBE13 (10 and 100 μM) [2]. SBE13 (66 and 100 μM) promotes cleavage of Cdc27 in HeLa cells and raises the levels of phospho-histone H3, Wee1, Emi1, and securin. Additionally, SBE13 (10 and 100 μM) can cause HeLa cells to undergo apoptosis [3].
SBE13 shows a high selectivity for Plk1 (IC50 = 200 pM) over Plk2 (IC50 > 66 µM) and Plk3 (IC50 = 875 nM), representing >4,000-fold selectivity. In primary cell lines, SBE13 induces a transient G2/G1 arrest with only minor effects on proliferation, unlike BI 2536 which causes stable G2/M arrest. SBE13 does not induce apoptosis in primary cells, mirroring the effects of specific Plk1 knockdown by RNAi. |
| ln Vivo |
In vivo, SBE13 has not been extensively characterized in animal models. Its in vitro selectivity profile suggests that it would produce fewer off-target effects than less selective Plk1 inhibitors. The compound is primarily used as a research tool to study Plk1 function in cancer cells and to validate Plk1 as a therapeutic target. No published in vivo efficacy data are available in the public domain.
|
| Enzyme Assay |
Plk1 kinase assays use recombinant Plk1 kinase domain and a fluorescent or radiolabeled peptide substrate. SBE13 is incubated with the kinase and substrate in assay buffer containing ATP. Phosphorylation is measured by fluorescence polarization or scintillation counting. IC50 values are calculated from dose-response curves. Type II binding is confirmed by co-crystallization or surface plasmon resonance.
|
| Cell Assay |
Cell-based assays use cancer cell lines (HeLa, HT29) and primary cell lines. Cells are treated with SBE13 (0.01-100 µM) for 24-72 h. Cell viability is measured by MTT assay. Cell cycle analysis is performed by flow cytometry after propidium iodide staining. Plk1 activity is assessed by measuring phosphorylation of downstream substrates (e.g., Cdc25C) by Western blotting.
|
| Animal Protocol |
In vivo studies with SBE13 are not well-documented. If conducted, a typical protocol would involve intraperitoneal or oral administration of SBE13 (1-30 mg/kg) in mouse xenograft models. Tumor volume would be measured, and Plk1 inhibition in tumor tissue would be assessed by measuring phospho-Cdc25C levels by immunohistochemistry.
|
| References |
|
| Molecular Formula |
C₂₄H₂₇CLN₂O₄
|
|---|---|
| Molecular Weight |
442.94
|
| Exact Mass |
442.165
|
| CAS # |
775294-82-1
|
| Related CAS # |
SBE13 Hydrochloride;1052532-15-6
|
| PubChem CID |
4719406
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
582.8±45.0 °C at 760 mmHg
|
| Flash Point |
306.3±28.7 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
3.88
|
| tPSA |
61.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
31
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(CCNCC2=CC=C(OCC3=CC=C(Cl)N=C3)C(OC)=C2)C=C1OC
|
| InChi Key |
XNPRQBVQOJZMMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H27ClN2O4/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3
|
| Chemical Name |
N-[[4-[(6-chloropyridin-3-yl)methoxy]-3-methoxyphenyl]methyl]-2-(3,4-dimethoxyphenyl)ethanamine
|
| Synonyms |
SBE13; SBE 13; SBE13 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2576 mL | 11.2882 mL | 22.5764 mL | |
| 5 mM | 0.4515 mL | 2.2576 mL | 4.5153 mL | |
| 10 mM | 0.2258 mL | 1.1288 mL | 2.2576 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.